Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Yunnan Cancer Hospital

ClinicalTrials.gov lists Yunnan Cancer Hospital as lead sponsor of 28 trials. It has 9 active development programs.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

19 0 2014 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 6 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 9 in 2026 and about 16 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Yunnan Cancer Hospital: 28 lead-sponsored trials and 0 legal-entity registrations.

Get the Yunnan Cancer Hospital report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (34)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Breast Neoplasms 16
Colorectal Neoplasms 10
Stomach Neoplasms 7
Rectal Neoplasms 6
Head and Neck Neoplasms 5

Trials by start year as sponsor or collaborator (10)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 6
2025 19
2024 13
2023 10
2022 6
2021 2
2020 1
2018 1
2017 2
2014 1

Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (9)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
TTP-ICG fluorescent probe Carcinoma, Transitional Cell Phase 2 1
TTP-ICG fluorescent probe Urinary Bladder Neoplasms Phase 2 1
Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy Colorectal Neoplasms Phase 2 1
Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy Rectal Neoplasms Phase 2 1
TTP-ICG NIR fluorescent diagnostic agent Non-Muscle Invasive Bladder Neoplasms Phase 1/2 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
1 of 1 hit target (n=1) 0 of 1 on time (n=1)

Journals published in (28)

Shown in this order: most published in first.

Journals published in
Journal Publications
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 4
Annals of oncology : official journal of the European Society for Medical Oncology 3
Annals of surgical oncology 3
CA: a cancer journal for clinicians 2
Frontiers in oncology 2

Organization relationships (12)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Shandong Cancer Hospital and Institute Co sponsors trial with 3
Sichuan Cancer Hospital and Research Institute Co sponsors trial with 2
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Co sponsors trial with 2
Longyan City First Hospital Co sponsors trial with 1
Hainan Cancer Hospital Co sponsors trial with 1

Latest dated events (61)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10-30 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-08-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-20 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (76)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial collaborator Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria
ALB Trial collaborator Named in trial inclusion criteria
ALK Trial collaborator Named in trial inclusion criteria
ALK Trial collaborator Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, approved assets, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.